Insulet Corporation

PODD

US45784P1012

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 01:30:00 03/07/2024 am IST			5-day change	1st Jan Change
197.2 ^USD	+0.53%		-4.16%	-9.12%

24/06	Transcript : Insulet Corporation - Special Call
22/06	Insulet Corporation Announces SECURE-T2d Pivotal Trial Results Demonstrate Omnipod 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes	CI

Insulet Corporation Reaffirms Revenue Guidance for the Year 2021

January 15, 2020 at 12:30 am IST

Insulet Corporation reaffirmed revenue guidance for the year 2021. The company is well on track to achieving the company's 2021 targets of $1 billion in revenue.

Latest news about Insulet Corporation

Transcript : Insulet Corporation - Special Call	24/06
Insulet Corporation Announces SECURE-T2d Pivotal Trial Results Demonstrate Omnipod 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes	22/06	CI
Insulet Launches Omnipod 5 Tubeless Insulin System in the UK, Netherlands	20/06	MT
Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands	20/06	CI
Insulet Insider Sold Shares Worth $299,940, According to a Recent SEC Filing	18/06	MT
Insulet Insider Sold Shares Worth $405,806, According to a Recent SEC Filing	12/06	MT
Insulet Insider Sold Shares Worth $1,333,570, According to a Recent SEC Filing	12/06	MT
Transcript : Insulet Corporation Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 09:00 AM	06/06
Redburn Atlantic Initiates Insulet With Buy Rating, $235 Price Target	30/05	MT
Insulet Insider Sold Shares Worth $596,970, According to a Recent SEC Filing	30/05	MT
Insulet Shares Rise Despite Blue Orca's Short Position	14/05	MT
Raymond James Adjusts Price Target on Insulet to $213 From $218	10/05	MT
Wolfe Research Raises Price Target on Insulet to $205 From $200	10/05	MT
Canaccord Genuity Adjusts Price Target on Insulet to $234 From $226	10/05	MT
Jefferies Raises Price Target on Insulet to $260 From $255	10/05	MT
Stifel Adjusts Price Target on Insulet to $185 From $208	10/05	MT
Insulet misses first-quarter profit estimates as marketing costs weigh	10/05	RE
Insulet Q1 Earnings, Revenue Rise; 2024 Revenue Growth Boosted	10/05	MT
Transcript : Insulet Corporation, Q1 2024 Earnings Call, May 09, 2024	10/05
Earnings Flash (PODD) INSULET CORPORATION Reports Q1 Revenue $441.7M, vs. Street Est of $423.5M	10/05	MT
Insulet Raises Full Year 2024 Revenue Growth Range to 14%-18%, vs Prior View of 12%-17%; Sees Q2 Revenue Growth of 15%-18%	10/05	MT
Insulet Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Insulet Corporation Provides Revenue Guidance for the Second Quarter Ending June 30, 2024	10/05	CI
Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024	10/05	CI
China trade heats up, UK rates in view	09/05	RE

Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (95.6%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (4.4%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). By the end of 2022, the group will have 2 production sites located in the United States and in China. The United States accounts for 72.2% of net sales.

Sector

Medical Equipment, Supplies & Distribution

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Insulet Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

197.2 USD

Average target price

233.6 USD

Spread / Average Target

+18.48%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
INSULET CORPORATION	-9.12%	13.81B
ABBOTT LABORATORIES	-6.24%	180B
MEDTRONIC PLC	-6.08%	99.21B
BECTON, DICKINSON AND COMPANY	-5.98%	66.25B
DEXCOM, INC.	-9.35%	44.74B
CENCORA, INC.	+8.34%	43.82B
HOYA CORPORATION	+10.35%	41.96B
METTLER-TOLEDO INTERNATIONAL, INC.	+11.88%	28.98B
WEST PHARMACEUTICAL SERVICES, INC.	-8.38%	23.5B
TERUMO CORPORATION	+16.18%	24.07B

Other Medical Equipment, Supplies & Distribution